Radiopharmaceuticals and Medical Imaging: Development of Radioimmumoconjugates for Radioimmunoimaging and Radioimmunotherapy of Malignant Diseases

Abstract

Radioimmunopharmaceuticals or radioimmunoconjugates (RICs) are using antibody (Ab) or antibody derivatives as targeting carriers, taking advantage of the specific binding between antibody and antigen. In this chapter, we will discuss several aspects of RIC development and their application in radioimmunoimaging (RII) and radioimmunotherapy (RIT) for malignant diseases, including lymphoma, prostate cancer, colon cancer, and breast and ovarian cancers.